BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 2308978)

  • 21. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
    Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
    Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
    Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
    Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
    Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
    Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID).
    Dickinson AM; Reid MM; Abinun M; Peak J; Brigham K; Dunn J; Cant AJ
    Bone Marrow Transplant; 1997 Feb; 19(4):323-9. PubMed ID: 9051241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
    Naparstek E; Or R; Nagler A; Cividalli G; Engelhard D; Aker M; Gimon Z; Manny N; Sacks T; Tochner Z
    Br J Haematol; 1995 Mar; 89(3):506-15. PubMed ID: 7734348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quantitative determination of human bone marrow T cells following in vitro depletion by Campath-1 monoclonal antibody].
    Irlé C; Kaestli M; Chapuis B; Jeannet M
    Schweiz Med Wochenschr; 1985 Oct; 115(43):1517-8. PubMed ID: 3909385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
    Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
    Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Application of monoclonal antibodies to bone marrow transplantation].
    Morishima Y
    Gan To Kagaku Ryoho; 1988 May; 15(5):1693-701. PubMed ID: 3285796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
    O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
    Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.
    Jacobs P; Wood L; Fullard L; Waldmann H; Hale G
    Bone Marrow Transplant; 1994 Jun; 13(6):763-9. PubMed ID: 7920312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
    Willemze R; Richel DJ; Falkenburg JH; Hale G; Waldmann H; Zwaan FE; Fibbe WE
    Bone Marrow Transplant; 1992 Apr; 9(4):255-61. PubMed ID: 1600413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in childhood: similar survival after matched-related and matched-unrelated donor transplants.
    Al-Kasim FA; Thornley I; Rolland M; Lau W; Tsang R; Freedman MH; Saunders EF; Calderwood S; Doyle JJ
    Br J Haematol; 2002 Feb; 116(2):483-90. PubMed ID: 11841456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance.
    Cobbold SP; Martin G; Qin S; Waldmann H
    Nature; 1986 Sep 11-17; 323(6084):164-6. PubMed ID: 3528866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity.
    Condiotti R; Nagler A
    Bone Marrow Transplant; 1996 Oct; 18(4):713-20. PubMed ID: 8899185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries.
    Clarke E; Potter MN; Hale G; Waldmann H; Lankester A; Cornish JM; Steward CG; Marks DI; Oakhill A; Pamphilon DH
    Bone Marrow Transplant; 1998 Jul; 22(2):117-24. PubMed ID: 9707017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.